


CLAIMS

What is claimed is:

1. A compound of formulae (I) or (II) having the structure



wherein

- R₁, R₂, R₃, R₄, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R₁₄, and R₁₅ are each, independently, hydrogen, R₁₇, monofluoroalkyl, monofluoroalkenyl, aryl-R₁₆⁻, heteroaryl-R₁₆⁻, hydroxyalkyl, HO-R₁₆⁻, R₁₇-X-R₁₆⁻, HS-R₁₆⁻, R₁₇-S(O)-, R₁₇-S(O)₂⁻, R₁₇-SO₃⁻, R₁₇-S(O)₂NR-, -N(R)₂, -NR-C(NH₂)=NR, cyano, nitro, halogen, -OR, -SR, -SO₃R, -S(O)₂N(R)₂, -C(O)R, -C(R)=N-OR, -C(NH₂)=NR, -CO₂R, -OC(O)R, or -C(O)N(R)₂; or are taken together with either R_{p+1} or R_{p-1} linked with an -alkylene-, or -X-alkylene- group;
- R₅ is hydrogen, R₁₇, monofluoroalkyl, monofluoroalkenyl, aryl-R₁₆⁻, heteroaryl-R₁₆⁻, hydroxyalkyl, HO-R₁₆⁻, R₁₇-X-R₁₆⁻, HS-R₁₆⁻, -CR(O), -CO₂R, or -C(O)N(R)₂; or R₅ may be taken together with either R₆ or R₇ and linked with an -alkylene- or -X-alkylene- group;
- R₆ is hydrogen, R₁₇, monofluoroalkyl, monofluoroalkenyl, aryl-R₁₆⁻, heteroaryl-R₁₆⁻, hydroxyalkyl, HO-R₁₆⁻, R₁₇-X-R₁₆⁻, HS-R₁₆⁻, -CR(O), -CO₂R, or -C(O)N(R)₂; or R₆ may be taken together with either R₅ or R₇ and linked with an -alkylene- or -X-alkylene- group;
- R₁₃ is R, R₁₇-X-R₁₆⁻, R₁₇-S(O)-, R₁₇-S(O)₂⁻, -SO₃R, -S(O)₂N(R)₂, or D-glucuronidate;

R_{16} is -alkylene-, -cycloalkylene-, -alkylene-X-alkylene-, -alkylene-X-cycloalkylene-, -cycloalkylene-X-alkylene-, or -cycloalkylene-X-cycloalkylene-;

R_{17} is alkyl, aryl, heteroaryl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, alkenyl-X-alkylene-, cycloalkenyl-X-alkylene-, or perfluoroalkyl;

R is, independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, monofluoroalkyl, perfluoroalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy-(C₂-C₆)alkyl, alkoxyalkyl, alkylthioalkyl, formyl, acyl, alkoxycarbonyl, -C(O)NH₂, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminoalkyl, or dialkylaminoalkyl; or when an atom contains two R groups, the R groups may be taken together linked with an -alkylene- group;

X is O, -NR-, -S(O)_m-, -C(O)-, -OC(O)-, -C(O)O-, -NRC(O)-, or -C(O)NR-;

m is 0, 1, or 2;

p is 2, 3, 6, 7, 8, 9, 12, 13, or 14;

R_{21} , R_{22} , R_{23} , R_{24} , R_{27} , R_{28} , R_{29} , R_{30} , R_{31} , R_{33} , R_{34} , and R_{35} are, independently, hydrogen, R_{17} , monofluoroalkyl, monofluoroalkenyl, aryl- R_{16} -, heteroaryl- R_{16} -, hydroxyalkyl, HO- R_{16} -, R_{17} -Y- R_{16} -, HS- R_{16} -, R_{17} -S(O)-, R_{17} -S(O)₂-, R_{17} -SO₃-, R_{17} -S(O)₂NR-, -N(R)₂, -NR-C(NH₂)=NR, cyano, nitro, halogen, -OR, -SR, -SO₃R, -S(O)₂N(R)₂, -C(O)R, -C(R)=N-OR, -C(NH₂)=NR, -CO₂R, -OC(O)R, or -C(O)N(R)₂; or are taken together with either R_{q+1} or R_{q-1} linked with an -alkylene-, or -Y-alkylene- group;

R_{25} is hydrogen, R_{17} , monofluoroalkyl, monofluoroalkenyl, aryl- R_{16} -, heteroaryl- R_{16} -, hydroxyalkyl, HO- R_{16} -, R_{17} -Y- R_{16} -, HS- R_{16} -, -CR(O), -CO₂R, or -C(O)N(R)₂; or R_{25} may be taken together with either R_{26} or R_{27} and linked with an -alkylene- or -Y-alkylene- group;

R_{26} is hydrogen, R_{17} , monofluoroalkyl, monofluoroalkenyl, aryl- R_{16} -, heteroaryl- R_{16} -, hydroxyalkyl, HO- R_{16} -, R_{17} -Y- R_{16} -, HS- R_{16} -, -CR(O), -CO₂R, or -C(O)N(R)₂; or R_{26} may be taken together with either R_{25} or R_{27} and linked with an -alkylene- or -Y-alkylene- group;

R_{32} is R, R_{17} -Y- R_{16} -, R_{17} -S(O)-, R_{17} -S(O)₂-, -SO₃R, -S(O)₂N(R)₂, or D-glucuronidate;

Y is O, -NR-, -S(O)_n-, -C(O)-, -OC(O)-, -C(O)O-, -NRC(O)-, or -C(O)NR-;

n is 0, 1, or 2;

q is 22, 23, 26, 27, 28, 29, 32, 33, or 34;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein the compound is of formula (I) or a pharmaceutical acceptable salt thereof.
3. The compound according to claim 2, wherein R_{13} is hydrogen, or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 3, wherein
 $R_1, R_2, R_3, R_4, R_7, R_8, R_9, R_{10}, R_{11}, R_{12}, R_{14},$ and R_{15} are each, independently, hydrogen, R_{17} , aryl- R_{16-} , $R_{17-X-R_{16-}}$, hydroxyalkyl, $HO-R_{16-}$, halogen, -OR, -COR, or $-CO_2R$;
 R_5 and R_6 are each, independently, hydrogen or R_{17} ;
 R_{16} is -alkylene-;
 R_{17} is alkyl, aryl, heteroaryl, or perfluoroalkyl;
 R is hydrogen or alkyl; or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 1, wherein the compound is of formula (II) or a pharmaceutical acceptable salt thereof.
6. The compound according to claim 5, wherein R_{32} is hydrogen, or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 6, wherein
 $R_{21}, R_{22}, R_{23}, R_{24}, R_{27}, R_{28}, R_{29}, R_{30}, R_{31}, R_{33}, R_{34},$ and R_{35} are each, independently, hydrogen, R_{17} , aryl- R_{16-} , $R_{17-Y-R_{16-}}$, hydroxyalkyl, $HO-R_{16-}$, halogen, -OR, -COR, or $-CO_2R$;
 R_{25} and R_{26} are each, independently, hydrogen or R_{17} ;
 R_{16} is -alkylene-;
 R_{17} is alkyl, aryl, heteroaryl, or perfluoroalkyl;
 R is hydrogen or alkyl; or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 1, which is
 - a) 4-[(6-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
 - b) 4-[[*(S)*-6-methylphenanthridin-5(6*H*)-yl]sulfonyl]phenol;
 - c) 4-[[*(R)*-6-methylphenanthridin-5(6*H*)-yl]sulfonyl]phenol;
 - d) 4-[(2-bromo-6-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
 - e) 2-methyl-4-[(6-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;

- f) 4-[(2-bromo-6-methylphenanthridin-5(6*H*)-yl)sulfonyl]-2-methylphenol;
- g) 4-[(6-butylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- h) 4-[(2-bromo-6-butylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- i) 4-[(6-phenylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- j) 4-[[*(S)*-6-phenylphenanthridin-5(6*H*)-yl]sulfonyl]phenol;
- k) 4-[[*(R)*-6-phenylphenanthridin-5(6*H*)-yl]sulfonyl]phenol;
- l) 4-[(2-bromo-6-phenylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- m) 2-bromo-4-[(2-bromo-6-phenylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- n) 4-[(6-*tert*-butylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- o) 4-[[*(R)*-6-*tert*-butylphenanthridin-5(6*H*)-yl]sulfonyl]phenol;
- p) 4-[[*(S)*-6-*tert*-butylphenanthridin-5(6*H*)-yl]sulfonyl]phenol;
- q) 4-[(2-bromo-6-*tert*-butylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- r) 4-[(6-ethylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- s) 4-[(2-bromo-6-ethylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- t) 4-[(6-ethylphenanthridin-5(6*H*)-yl)sulfonyl]-2-methylphenol;
- u) 4-[(2-bromo-6-ethylphenanthridin-5(6*H*)-yl)sulfonyl]-2-methylphenol;
- v) 4-[[*(S*^{*})-6-[(*R*^{*})-1-methylpropyl]phenanthridin-5(6*H*)-yl]sulfonyl]phenol;
- w) 4-[(6-methylphenanthridin-5(6*H*)-yl)sulfonyl]benzene-1,2-diol;
- x) 2-hydroxy-5-[(6-methylphenanthridin-5(6*H*)-yl)sulfonyl]benzoic acid;
- y) ethyl 2-ethoxy-5-[(6-methylphenanthridin-5(6*H*)-yl)sulfonyl]benzoate;
- z) 2-(hydroxymethyl)-4-[(6-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- aa) 2-hydroxy-5-[(6-methylphenanthridin-5(6*H*)-yl)sulfonyl]benzaldehyde;
- bb) 4-[(6-ethyl-2-thien-3-ylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- cc) 4-[[6-ethyl-2-(3-methoxyphenyl)phenanthridin-5(6*H*)-yl]sulfonyl]phenol;
- dd) 3-{6-ethyl-5-[(4-hydroxyphenyl)sulfonyl]-5,6-dihydrophenanthridin-2-yl}phenol;
- ee) 4-[(2-dibenzo[*b,d*]furan-4-yl-6-ethylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- ff) 4-[(8-fluoro-6-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- gg) 4-[[*(S)*-8-fluoro-6-methylphenanthridin-5(6*H*)-yl]sulfonyl]phenol;
- hh) 4-[[*(R)*-8-fluoro-6-methylphenanthridin-5(6*H*)-yl]sulfonyl]phenol;
- ii) 4-[(8-fluoro-6-methylphenanthridin-5(6*H*)-yl)sulfonyl]-2-methylphenol;
- jj) 5-[(4-hydroxyphenyl)sulfonyl]-6-methyl-5,6-dihydrophenanthridin-9-ol;
- kk) 5-[(4-hydroxy-3-methylphenyl)sulfonyl]-6-methyl-5,6-dihydrophenanthridin-9-ol;


- ll) 5-[(4-hydroxy-3-methylphenyl)sulfonyl]-6-methyl-5,6-dihydrophenanthridin-7-ol;
- mm) 5-[(4-hydroxyphenyl)sulfonyl]-6-methyl-5,6-dihydrophenanthridin-7-ol;
- nn) 4-[(6-ethyl-8-fluorophenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- oo) 4-[(6-ethyl-8-fluorophenanthridin-5(6*H*)-yl)sulfonyl]-2-methylphenol;
- pp) 4-[(6-ethyl-7-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- qq) 4-[(6-ethyl-9-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- rr) 4-[(2-bromo-6-ethyl-8-fluorophenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- ss) 4-[(2-bromo-8-fluoro-6-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- tt) 2-chloro-4-[(6-ethyl-8-fluorophenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- uu) 4-[(6-ethyl-8-fluoro-2-phenylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- vv) 3-[(8-fluoro-6-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- ww) 2-fluoro-4-[(8-fluoro-6-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- xx) 4-[(8-fluoro-6-methylphenanthridin-5(6*H*)-yl)sulfonyl]benzene-1,2-diol;
- yy) 4-[(6-ethyl-8-fluoro-2-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- zz) 4-[(6-ethyl-8-fluoro-2-thien-3-ylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- aaa) 4-[(6-ethyl-8-fluorophenanthridin-5(6*H*)-yl)sulfonyl]phenyl 3,3-dimethylbutanoate;
- bbb) 4-[(6-ethyl-8-fluorophenanthridin-5(6*H*)-yl)sulfonyl]phenyl propionate;
- ccc) 4-[(6-ethyl-8-fluorophenanthridin-5(6*H*)-yl)sulfonyl]phenyl benzoate;
- ddd) 2-fluoro-4-[(6-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- eee) 4-[(2-bromo-6-methylphenanthridin-5(6*H*)-yl)sulfonyl]-2-fluorophenol;
- fff) 4-[(6-methylphenanthridin-5(6*H*)-yl)sulfonyl]-2-(trifluoromethyl)phenol;
- ggg) 2,6-dimethyl-4-[(6-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- hhh) 4-[(6,8-dimethylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- iii) 4-[(8-chloro-6-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- jjj) 4-[(2-bromo-8-chloro-6-methylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- kkk) 2-{6-ethyl-5-[(4-hydroxyphenyl)sulfonyl]-5,6-dihydrophenanthridin-2-yl}phenol;
- lll) 4-[(6-ethyl-2-[4-(methylthio)phenyl]phenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- mmm) 4-[(6-ethyl-2-[(*E*)-2-phenylethenyl]phenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- nnn) 4-[[2-(1,1'-biphenyl-4-yl)-6-ethylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- ooo) 4-[[2-(3-chlorophenyl)-6-ethylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- ppp) 4-[(6-ethyl-2-quinolin-8-ylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- qqq) 4-[(6-ethyl-2-phenylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;

- rrr) 4-[[6-ethyl-2-(2-methylphenyl)phenanthridin-5(6*H*)-yl]sulfonyl}phenol;
- sss) 4-[(6-ethyl-2-thianthren-1-ylphenanthridin-5(6*H*)-yl)sulfonyl]phenol;
- ttt) 4-[[2-(1-benzofuran-2-yl)-6-ethylphenanthridin-5(6*H*)-yl]sulfonyl}phenol;
- uuu) 4-[[6-ethyl-2-(4-hydroxyphenyl)phenanthridin-5(6*H*)-yl]sulfonyl}phenol;
- vvv) 4-[[2-(2-chlorophenyl)-6-ethylphenanthridin-5(6*H*)-yl]sulfonyl}phenol;
- www) 4-[[6-ethyl-2-(4-ethylphenyl)phenanthridin-5(6*H*)-yl]sulfonyl}phenol;
- xxx) 1-(5-{6-ethyl-5-[(4-hydroxyphenyl)sulfonyl]-5,6-dihydrophenanthridin-2-yl}thien-2-yl)ethanone;
- yyy) 5-{6-ethyl-5-[(4-hydroxyphenyl)sulfonyl]-5,6-dihydrophenanthridin-2-yl}pyrimidine-2,4-diol;
- zzz) 4-[[6-ethyl-2-(2-hydroxyphenyl)phenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;
- aaaa) 4-[(6-ethyl-2-thien-3-ylphenanthridin-5(6*H*)-yl)sulfonyl]-2-methylphenol;
- bbbb) 4-[[6-ethyl-2-[4-(methylthio)phenyl]phenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;
- cccc) 4-[[6-ethyl-2-[(*E*)-2-phenylethenyl]phenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;
- dddd) 4-{6-ethyl-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-5,6-dihydrophenanthridin-2-yl}benzene-1,2-diol;
- eeee) 4-[[2-(1,1'-biphenyl-4-yl)-6-ethylphenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;
- ffff) 4-[[6-ethyl-2-(3-hydroxyphenyl)phenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;
- gggg) 4-[[2-(3-chlorophenyl)-6-ethylphenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;
- hhhh) 4-[[6-ethyl-2-[(*E*)-hept-1-enyl]phenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;
- iiii) 4-[(6-ethyl-2-pyridin-4-ylphenanthridin-5(6*H*)-yl)sulfonyl]-2-methylphenol;
- jjjj) 4-[(6-ethyl-2-quinolin-8-ylphenanthridin-5(6*H*)-yl)sulfonyl]-2-methylphenol;
- kkkk) 4-[[6-ethyl-2-(2-methylphenyl)phenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;
- llll) 4-[[2-(1-benzothien-2-yl)-6-ethylphenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;
- mmmm) 4-[[2-(1-benzothien-3-yl)-6-ethylphenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;


- nnnn) 4-[(2-dibenzo[*b,d*]furan-4-yl-6-ethylphenanthridin-5(6*H*)-yl)sulfonyl]-2-methylphenol;
- oooo) 4-[[2-(1-benzofuran-2-yl)-6-ethylphenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;
- pppp) 4-[[6-ethyl-2-(4-hydroxyphenyl)phenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;
- qqqq) 4-[[2-(2-chlorophenyl)-6-ethylphenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;
- rrrr) 4-[[6-ethyl-2-(4-ethylphenyl)phenanthridin-5(6*H*)-yl]sulfonyl]-2-methylphenol;
- ssss) 1-(5-{6-ethyl-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-5,6-dihydrophenanthridin-2-yl}thien-2-yl)ethanone;
- tttt) 5-{6-ethyl-5-[(4-hydroxy-3-methylphenyl)sulfonyl]-5,6-dihydrophenanthridin-2-yl}pyrimidine-2,4-diol,

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition, which comprises a compound of formulae (I) or (II) having the structure



(I)



(II)

wherein

R_1 , R_2 , R_3 , R_4 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , R_{14} , and R_{15} are each, independently, hydrogen, R_{17} , monofluoroalkyl, monofluoroalkenyl, aryl- R_{16^-} , heteroaryl- R_{16^-} , hydroxyalkyl, HO- R_{16^-} , R_{17} -X- R_{16^-} , HS- R_{16^-} , R_{17} -S(O)-, R_{17} -S(O)₂-, R_{17} -SO₃-, R_{17} -S(O)₂NR-, -N(R)₂, -NR-C(NH₂)=NR, cyano, nitro, halogen, -OR, -SR, -SO₃R, -S(O)₂N(R)₂, -C(O)R, -C(R)=N-OR, -C(NH₂)=NR, -CO₂R, -OC(O)R, or -C(O)N(R)₂; or are taken together with either R_{p+1} or R_{p-1} linked with an -alkylene-, or -X-alkylene-group;

- R_5 is hydrogen, R_{17} , monofluoroalkyl, monofluoroalkenyl, aryl- R_{16} -, heteroaryl- R_{16} -, hydroxyalkyl, HO- R_{16} -, R_{17} -X- R_{16} -, HS- R_{16} -, -CR(O), -CO₂R, or -C(O)N(R)₂; or R_5 may be taken together with either R_6 or R_7 and linked with an -alkylene- or -X-alkylene- group;
- R_6 is hydrogen, R_{17} , monofluoroalkyl, monofluoroalkenyl, aryl- R_{16} -, heteroaryl- R_{16} -, hydroxyalkyl, HO- R_{16} -, R_{17} -X- R_{16} -, HS- R_{16} -, -CR(O), -CO₂R, or -C(O)N(R)₂; or R_6 may be taken together with either R_5 or R_7 and linked with an -alkylene- or -X-alkylene- group;
- R_{13} is R, R_{17} -X- R_{16} -, R_{17} -S(O)-, R_{17} -S(O)₂-, -SO₃R, -S(O)₂N(R)₂, or D-glucuronidate;
- R_{16} is -alkylene-, -cycloalkylene-, -alkylene-X-alkylene-, -alkylene-X-cycloalkylene-, -cycloalkylene-X-alkylene-, or -cycloalkylene-X-cycloalkylene-;
- R_{17} is alkyl, aryl, heteroaryl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, alkenyl-X-alkylene-, cycloalkenyl-X-alkylene-, or perfluoroalkyl;
- R is, independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, monofluoroalkyl, perfluoroalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy-(C₂-C₆)alkyl, alkoxyalkyl, alkylthioalkyl, formyl, acyl, alkoxycarbonyl, -C(O)NH₂, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminoalkyl, or dialkylaminoalkyl; or when an atom contains two R groups, the R groups may be taken together linked with an -alkylene- group;
- X is O, -NR-, -S(O)_m-, -C(O)-, -OC(O)-, -C(O)O-, -NRC(O)-, or -C(O)NR-;
- m is 0, 1, or 2;
- p is 2, 3, 6, 7, 8, 9, 12, 13, or 14;
- R_{21} , R_{22} , R_{23} , R_{24} , R_{27} , R_{28} , R_{29} , R_{30} , R_{31} , R_{33} , R_{34} , and R_{35} are, independently, hydrogen, R_{17} ; monofluoroalkyl, monofluoroalkenyl, aryl- R_{16} -, heteroaryl- R_{16} -, hydroxyalkyl, HO- R_{16} -, R_{17} -Y- R_{16} -, HS- R_{16} -, R_{17} -S(O)-, R_{17} -S(O)₂-, R_{17} -SO₃-, R_{17} -S(O)₂NR-, -N(R)₂, -NR-C(NH₂)=NR, cyano, nitro, halogen, -OR, -SR, -SO₃R, -S(O)₂N(R)₂, -C(O)R, -C(R)=N-OR, -C(NH₂)=NR, -CO₂R, -OC(O)R, or -C(O)N(R)₂; or are taken together with either R_{q+1} or R_{q-1} linked with an -alkylene-, or -Y-alkylene- group;
- R_{25} is hydrogen, R_{17} , monofluoroalkyl, monofluoroalkenyl, aryl- R_{16} -, heteroaryl- R_{16} -, hydroxyalkyl, HO- R_{16} -, R_{17} -Y- R_{16} -, HS- R_{16} -, -CR(O), -CO₂R, or -C(O)N(R)₂; or R_{25} may be taken together with either R_{26} or R_{27} and linked with an -alkylene- or -Y-alkylene- group;

R_{26} is hydrogen, R_{17} , monofluoroalkyl, monofluoroalkenyl, aryl- R_{16} -, heteroaryl- R_{16} -, hydroxyalkyl, HO- R_{16} -, R_{17} -Y- R_{16} -, HS- R_{16} -, -CR(O), -CO₂R, or -C(O)N(R)₂; or R_{26} may be taken together with either R_{25} or R_{27} and linked with an -alkylene- or -Y-alkylene- group;

R_{32} is R, R_{17} -Y- R_{16} -, R_{17} -S(O)-, R_{17} -S(O)₂-, -SO₃R, -S(O)₂N(R)₂, or D-glucuronidate;

Y is O, -NR-, -S(O)_n-, -C(O)-, -OC(O)-, -C(O)O-, -NRC(O)-, or -C(O)NR-;

n is 0, 1, or 2;

q is 22, 23, 26, 27, 28, 29, 32, 33, or 34;

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. A method of treating or inhibiting chronic inflammatory disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of claim 1.

11. A method of treating or inhibiting rheumatoid arthritis, spondyloarthropathies, osteoarthritis, psoriatic arthritis, or juvenile arthritis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of claim 1.

12. A method of treating or inhibiting inflammatory bowel disease, Crohn's disease, ulcerative colitis, or indeterminate colitis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of claim 1.

13. A method of treating or inhibiting psoriasis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of claim 1.

14. A method of treating or inhibiting asthma or chronic obstructive pulmonary disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of claim 1.

15. A method of treating or inhibiting stroke, ischemia, or reperfusion injury in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of claim 1.

16. A method of lowering cholesterol, triglycerides, Lp(a), and LDL levels; inhibiting or treating hypercholesteremia, hyperlipidemia, cardiovascular disease, atherosclerosis, acute coronary syndrome, peripheral vascular disease, restenosis, or vasospasm in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of claim 1.

17. A method of treating or inhibiting Alzheimer's disease, cognitive decline, or senile dementia in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of claim 1.

18. A method of treating or inhibiting type II diabetes in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of claim 1.

19. A method of treating or inhibiting sepsis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of claim 1.